Purpose: The variable regions of Ig (idiotype, Id) expressed by malignant B cells can be used as tumorspecific antigens that induce humoral and cellular immunity. However, epitopes derived from Id that stimulate human CD8 þ T-cell immunity are incompletely characterized.
Introduction
B-cell malignancies express unique variable region determinants in their surface Ig receptor (idiotype, Id) that can serve as tumor-specific antigens. Studies in mice and humans showed that humoral and cellular immune responses were induced following Id vaccination (1) (2) (3) (4) . We have previously shown that autologous Id protein can be formulated into an immunogenic antigen in lymphoma patients, by conjugation with a carrier protein, keyhole limpet hemocyanin (KLH), and administration with granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvant. Lymphoma-specific CD8 þ T-cell responses were associated with achievement of molecular remissions (3) . In human myeloma patients, T-cell responses specific for Id protein have generally been shown, suggesting immunogenicity of this tumor antigen (5) . Finally, a randomized phase III clinical trial of an Id protein vaccine recently has shown prolonged remission duration in follicular lymphoma (FL) patients in first remission (6) . However, the immunogenic epitopes derived from Id that stimulates CD8 þ T-cell responses have been incompletely characterized, especially Id light chain (V L ) determinants. Despite the availability of new proteasome inhibitors and other targeted agents, disease relapse still remains a major problem for myeloma patients, and even high-dose therapy followed by autologous stem cell transplantation (SCT) in tandem does not seem to be curative for this disease (7) . In contrast, allogeneic SCT following either myeloablative or reduced intensity conditioning has been shown to induce prolonged disease-free survival in a small percentage of patients, suggesting a possible graft-versusmyeloma (GVM) effect (8) . Attempts to enhance the GVM effect by donor lymphocyte infusions (DLI) have resulted in an increased incidence of graft-versus-host disease (GVHD; ref. 9) . Therefore, strategies to enhance the specific antitumor effect of the graft without increasing the risk of GVHD are needed to improve outcome in allotransplant recipients.
One novel strategy is to transfer highly enriched populations of tumor antigen-specific T cells from donor to recipient (i.e., educated DLIs) to enhance the antitumor effect of the allograft without exacerbating GVHD. The approach of allogeneic marrow donor immunization in myeloma has been tested clinically in a small number of HLA-matched donor-recipient pairs and donor immunization with Id protein has proved safe (10, 11) . As an alternative to vaccinating donors in vivo in future clinical studies, we develop here a method to prime and expand donor Id light chain-specific T cells in vitro with the goal of using Id-specific DLI as the transfer element against B-cell malignancies in future clinical studies.
Materials and Methods

Human tumors
U266 myeloma cell line (HLA-A*0201/A3 þ ) was obtained from American Type Culture Collection. HLA-A*0201 primary FL or chronic lymphocytic leukemia (CLL) tumors were purified from patient's blood or spleen with HISTOPAQUE-1077 (Sigma) and B-cell isolation kit (Miltenyi Biotec). HLA-A*0201 primary plasma cell leukemia (PL) cells were isolated with CD138 þ cell isolation kit (Miltenyi Biotec). All patients' samples were collected before the administration of high-does therapy or Id vaccination. This study was approved by the Institutional Review Board Committee, and informed consent was obtained in accordance with the Declaration of Helsinki.
Reverse transcriptase PCR of Id light chain cDNA A total of 3 mg RNA was extracted from U266, and primary tumors were reverse-transcribed into cDNA with SuperScript III Kit from Invitrogen (catalogue no. 11745100). The highly variable region of Id light chain region was PCR amplified with primers from a published article (12) . The PCR conditions were as follows: 94 C, 5 minutes, followed by 94 C, 30 seconds and 58 C, 30 seconds; 72 C, 45 seconds for 35 cycles; and 72 C, 9 minute. The PCR product was cloned into PCR2.1 TOPO vector (Invitrogen; catalogue no. K2000-01) and sequenced in the DNA core facility of MD Anderson Cancer Center.
Peptide synthesis and T2 binding
Peptides predicted to bind to HLA-A*0201 were synthesized to greater than 70% purity, dissolved in 100% dimethyl sulfoxide (DMSO; Sigma), and the binding affinity to HLA-A*0201 molecules was measured with T2 cells according to published methods (13) . In brief, T2 cells were incubated with 50 mg/mL peptides and 3 mg/mL of b 2 -microglobulin (Sigma; catalogue no. M4890) for overnight. The cells were then washed and incubated with phycoerythrin (PE)-labeled anti-HLA-A0201 monoclonal antibody (mAb; clone BB7.2; BD Biosciences) for 30 minutes at 4 C. After washes and fixation, cells were analyzed for the levels of HLA-A2 expression by flow cytometry. The binding affinity of peptide was quantified according to the formula [(mean fluorescence with peptide À mean fluorescence without peptide)/mean fluorescence without peptide] Â 100%. Influenza A virus M1 58-66 (GILGFVFTL) peptide was used as a positive control.
Generation of peptide-specific CTLs
The CTLs were generated from HLA-A*0201 normal donor peripheral blood mononuclear cells (PBMC) using reported methods (14) . Briefly, PBMCs (1 Â 10 5 cells/well) were incubated with 10 mg/mL peptide in quadruplicate in 96-well U-bottom microculture plates in 200 mL culture medium (50% AIM-V, 50% RPMI-1640, 10% human AB serum, and 100 IU/mL IL-2) and restimulated with peptide every 3 days. After 5 stimulations, T cells were stimulated with peptide-pulsed T2 cells and IFN-g production was determined in supernatants by ELISA. CD8 þ T cells were isolated from IFN-g-producing cultures by magnetic-activated cell sorting and expanded by rapid expansion protocol (15) . Influenza A virus M1 58-66 (GILGFVFTL) peptide was used as a positive control.
Cytotoxicity U266 and primary tumor cells were labeled with 51 Cr, and standard 4-hour cytotoxicity assay was conducted. Anti-human HLA-ABC (clone W6/32; eBiosciences), anti-HLA-DR, DP, and DQ (clone T € U39; BD Biosciences), and mouse IgG2a isotype control (eBiosciences; catalogue no. 16-4724-81) were used to determine HLA restriction. All assays were conducted in triplicate and repeated 3 times.
Intracellular cytokine staining assay
Effector T cells were mixed with T2 or antigen-presenting cells (APC) loaded with 10 mg/mL peptide in a 1:1 ratio. Two hours later, 5 mg/mL Brefeldin A (Sigma) was added to block the transfer of Golgi part. The staining of intracellular cytokine was carried out with BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit 12 hours later. A total of 10 mL mouse anti-human IFN-g (clone 25723.11; BD Biosciences), mouse anti-human TNF-a (clone MAb11; BD Biosciences), mouse anti-human GM-CSF (clone 4H1; eBiosciences), mouse anti-human IL-4 (clone 8D4;
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Despite improvements in high-dose therapy followed by autologous stem cell transplantation (SCT), disease relapse still remains a major problem for B-cell malignancy patients, and even tandem autografts do not seem to be curative for these diseases. Allogeneic SCT following either myeloablative or reduced intensity conditioning has been shown to induce prolonged disease-free survival in a small percentage of patients, suggesting a possible graft-versus-myeloma effect. The ability to prime tumor-specific T cells derived from normal HLAmatched donors, rather than autologous patients, may have direct application to current adoptive transfer strategies already in clinical testing.
BD Biosciences), mouse anti-human IL-10 (clone JES3-9D7; eBiosciences), mouse anti-human IL-17 (clone eBio64DEC17; eBiosciences), and mouse anti-human CD8 (clone HIT8a; BD Biosciences) were added to the 100 mL effector T cells and stained for 30 minutes at 4 C in the dark. After 2 times washes in 1Â Perm Buffer, the samples were analyzed by flow cytometry and the data were analyzed with CellQuest software or FlowJo.
Statistical analysis
The Student t test was used to compare various experimental groups. Unless otherwise indicated, the mean average and SDs of triplicate wells are shown.
Results
Generation of Id V L -specific T-cell lines from normal donors
As a model, we used peptides derived from the V L of human U266 myeloma cell line to generate CTLs. Eighteen peptides from l V L of U266 were selected on the basis of the predicted binding affinity to HLA-A*0201 (http://wwwbimas.cit.nih.gov/mol bio/hla_bind/). Most peptides showed modest binding capacity to HLA-A*0201 molecules (T2 binding index: 0.15-1.29; Table 1 ). As peptides of low affinity are capable of inducing CTLs (16), all were used to generate CTLs from HLA-A*0201 normal donors (14) . Nine U266 peptides (P19, P20, P21, P23, P25, P26, P27, P28, and P29) induced CTLs that specifically secreted IFN-g when cocultured with peptide-pulsed T2 cells (Fig. 1A) . These peptides induced 54 CTLs in 10 HLA-A*0201 donors (Table 2) , confirming their immunogenicity in general normal donors. Using intracellular cytokine assay, we showed that CTLs produced IFN-g, TNF-a, and GM-CSF but not IL-4, IL-10, or IL-17 cytokines (Fig. 1C) . Next, we used 105 candidate peptides from V L of CLL (n ¼ 1), FL (n ¼ 3), and PL (n ¼ 1) tumor cells and showed that 5 primary Id V L -derived peptides are also immunogenic to generate 14 CTLs from 10 normal donors (Fig. 1B and Table 2 ).
Cytotoxicity of V L peptide-specific donor T cells
We expanded peptide-specific CTLs and assayed for cytotoxicity against peptide-pulsed T2 cells and primary tumors. Both U266 peptide-specific CTLs ( Fig. 2A) and CTLs generated against V L peptides from primary tumors (Fig. 2B) (Fig. 3A) . Donor-derived CTLs raised against primary tumor-derived V L peptides also specifically lysed primary tumors but not tumors expressing irrelevant Ids, or the respective patients' PBMCs (Fig. 3B ) or K562 cells (not shown).
To further characterize effector T cells, we assayed for inhibition of tumor cell lysis by HLA-blocking antibodies. We observed that HLA class I, but not class II, or isotype control antibodies inhibited cytolysis by U266 peptidespecific CTL lines (Fig. 4A) . HLA class I antibodies also inhibited the lysis of primary tumor cells by CTL raised against their respective V L peptides, suggesting that V L peptides were processed and presented on HLA class I molecules by both U266 and primary B-cell tumors (Fig. 4B) .
Candidate V L epitopes shared by human FL
A current limitation of Id vaccines is the requirement for individualized manufacture, which could be partially overcome by identification of universal T-cell epitopes shared by multiple patients. To determine whether the immunogenic U266 and primary tumor V L peptides were shared by other human B-cell tumors, we compared them to 90 l and 123 k light chain sequences from a panel of FL tumors (D. Gold, unpublished data). Interestingly, we observed that 12 FL tumors shared the P21 sequence whereas 1 FL each shared P19 and P25 epitopes. Seven FLs shared the L50 epitope, 2 FLs each shared the L53, L54, and L61 epitopes, and K18 and L10 epitopes were shared by one other primary FL each ( Table 1 ). The two 2 most frequently shared peptides (P21 and L50) localized to the framework regions of V L and consisted of germ line sequences without somatic mutation. Overall, 27 of 90 (30%) FL tumors expressing l light chain shared at least 1 of 13 epitopes we identified. Analysis of shared k epitopes will require additional studies, as only a single immunogenic k epitope was identified here.
To determine whether CTLs generated against a U266 peptide could lyse primary tumor cells expressing a shared epitope, we incubated donor-derived, P21-specific CTLs with HLA-A*0201 FL that expressed the P21 epitope (FL4, HLA-A2 þ /P21 þ ). We observed significant lysis of FL target cells, but not PBMCs, from this patient or FL that did not express P21 (FL5, HLA-A2 þ /P21 À ), suggesting specificity for Id (Fig. 4C) . 
Discussion
Increasing data suggest that human T-cell immunity plays an important role in antitumor effects induced by Id vaccination with whole protein (17) (18) (19) . Studies have identified T-cell epitopes harbored by Ig V H of human and Ig V L of murine B-cell tumors (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , but whether human Id V L harbor important T cell epitope remains unclear (25, 26) . Two previous publications reported that Ig light chains contained few T-cell epitopes. In Dabadghao's study, PBMCs from 5 myeloma patients were incubated with fragment F(ab) 2 , Fab, HC (heavy chain), or LC (light chain) of autologous Id protein to determine Id-specific T-cell proliferation. They found (25) . In the study by Fagerberg and colleagues, peptides corresponding to the heavy chain and light chain of 1 myeloma Id protein were synthesized and incubated with 1 myeloma patient's PBMCs. Using ELISPOT assay, they found that only peptides derived from HC but none from LC of Id protein could stimulate T cells to secrete IFN-g (26) . In our study, we have identified 14 peptides from Ig light chain (V L ) of U266 and primary B-cell tumors that can be used to generate 68 CTLs lines in vitro. These V L CTLs lysed the peptide-pulsed T2 cell as well as tumor cells, indicating that V L immunogenic epitopes are processed and presented by tumor cells. The differences between our results and previous studies may have resulted from several reasons. First, the patient's PBMCs are not ideal to study protective T-cell immunity, as the immune balance is skewed toward immunosuppression (30) . Second, the whole Id protein may harbor immune regulatory as well as stimulatory sequences, thus the identification of immunogenic epitope may be hampered by regulatory epitopes on the whole Id protein (31) Finally, significantly more peptides from patients were synthesized and tested in our study. Overall, our study suggests that immunogenic epitopes are present in V L complementarity determining regions and framework regions and are processed and presented by primary tumor cells and supports strategies for targeting V L epitopes on B-cell tumors. CTLs targeting Id V L may also have specific clinical usage against L chain-only secreting plasma cell dyscrasias (27) .
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Id vaccination significantly extended the disease-free survival of FL patients as shown in a recent controlled phase III trial, consistent with suggestions from prior pilot clinical trials (6, 32) . The ability to prime HLA-A2 þ donor CD8 þ T cells against Ig V L epitopes may provide a strategy for improving adoptive therapy against B-cell malignancies. Previous work in human SCT, showing that the transfer of humoral, and to a lesser extent cellular, antigen-specific immunity to clinically important viral antigens from immune donors to recipients can occur, provides a rationale for transferring tumor antigen-specific immunity induced in donors (33) (34) (35) . Vaccination of HLA-matched sibling donors with myeloma Id protein, with subsequent transfer of Id-specific immunity by SCT, has been shown to be feasible in a limited number of patients with myeloma (10, 11) . Six donors were vaccinated with Id proteins (conjugated to KLH) isolated from the plasma of the myeloma patients prior to marrow harvest, and respective recipients were administered booster Id immunizations following transplantation. The vaccine was well tolerated by all donors and recipients. With median follow-up of 8 years, no longterm toxicity has been observed in any immunized donor. Vaccination induced specific cellular and/or humoral immune responses against Id and the vaccine carrier KLH in all donors. Two patients died within 30 days of SCT because of transplant-related complications, but Idspecific and KLH-specific T-cell responses were detected in all 4 remaining patients post-but not pre-bone marrow transplantation. All 4 surviving patients converted from partial to complete responses following SCT. Taken together, these preliminary results suggest that (i) Id protein can elicit a specific immune response in a healthy donor, (ii) direct transfer of Id-specific T-cell immunity can occur from donor to recipient, and (iii) donor-derived T-cell responses may not be blocked by circulating Id protein present in the patients during and after SCT, or by iatrogenic immunosuppression for GVHD prophylaxis. Our current data suggest that as an alternative to donor vaccination, immunogenic peptides may be used to selectively expand Id-specific T cells ex vivo to generate "educated" DLIs. Such primed T cells might enhance tumor specificity and limit GVHD complications of current DLI strategies. Using a recently described method (14), we completed multiple T-cell stimulations within 2 weeks, such that the T cells are not exhausted at that time. Instead, these T cells are at much younger stage than T cells traditionally stimulated 3 to 4 times weekly. Even after these multiple stimulations, we observed that the T cells retained effector function and were able to lyse peptide-pulsed and tumor cell targets (Figs. 2 and 3 ). Furthermore, as described, using an established rapid expansion protocol, we showed feasibility of expanding such Id-specific T cells in large numbers. We are thus now in a position to conduct future in vivo experiments to determine whether adoptively transferred T cells recognizing shared epitopes would persist and be active.
Finally, although outside of the scope of the current study, one of the important questions in human tumor immunology is to determine whether autologous tumorspecific CTLs preexist in patients. In light of the immunogenicity of Id light chain peptides found in this study, specifically, it will be important to determine whether Ig light chain-specific CTLs preexist in the blood of patients with B-cell tumors and whether such precursors can be expanded by vaccination or adoptive transfer. Previous studies have suggested the existence and function of such tumor-specific T cells in B-cell tumor patients (36, 37) . Experiments testing the ability of human tumor V L peptides to generate autologous Id-specific T cells are under active investigation in our laboratory.
Disclosure of Potential Conflicts of Interest
L.W. Kwak received commercial research grant from Celgene, has ownership interest in XEME BioPharma, Inc., and is a consultant/advisory board member of Biovest International, Inc., and Antigenics Inc.
